G醫(yī)藥流通公司戰(zhàn)略管理研究
[Abstract]:With the deepening of medical reform, the government has introduced various medical reform policies to comprehensively regulate drug prices, which makes the pharmaceutical circulation industry with low gross profit rate worse, and the G pharmaceutical circulation company in which the author is located in Zhejiang Province, where the private economy is developed. There is fierce competition in the pharmaceutical circulation market. Under the condition of continuous deepening of the medical reform, under the circumstances of the pharmaceutical bidding, the constant reduction of prices by buyers and suppliers, and the repeated renegotiation of prices by hospitals, and the explosion of e-commerce companies, the growth rate of sales in the enterprise market has become weak. Profit space is further compressed. How to adapt to the development strategy of G pharmaceutical circulation company in the environment of industry innovation and upgrade, to develop itself and catch up with its competitors, and to make G pharmaceutical circulation company keep the leading position of Zhejiang regional industry is the main purpose of this paper. This paper takes the strategic management of G Pharmaceutical Circulation Company as the research object, through a series of interviews and other methods, carries on the extensive and thorough investigation to the G Medicine Circulation Company. Therefore, the paper is divided into six parts: the first part introduces the research background and then makes a related literature review, and finally puts forward the research framework of the paper; the second part introduces the current situation and difficulties of the company; the third part is the analysis of the related external environment. By using PEST model and Porter's five forces competition model, the paper analyzes the current situation of G pharmaceutical circulation company, the fourth part is the analysis of the internal resources and capability of G company, and the development strategy of G company is derived by using SWOT analysis. The fifth part is the choice of the development strategy, the implementation guarantee and the implementation effect evaluation of G Pharmaceutical Circulation Company, the sixth part is the summary and prospect. The main innovation point of this paper is to analyze the advantages and disadvantages, opportunities and threats of the company in the era of the rise of the Internet, and to formulate a strategy of differentiation suitable for itself in combination with its own characteristics. To create their own regional competitive advantage.
【學位授予單位】:華東理工大學
【學位級別】:碩士
【學位授予年份】:2017
【分類號】:F426.72;F252
【參考文獻】
相關期刊論文 前10條
1 譚曉林;孫太清;王超;楊芳;;價值創(chuàng)新:電子商務模式創(chuàng)新的關鍵[J];合作經濟與科技;2015年20期
2 董華華;;互聯(lián)網金融“攪局”下的“鲇魚效應”與價值創(chuàng)新[J];中國管理信息化;2015年13期
3 韓璐;;平安的“三網”合一新型醫(yī)療[J];二十一世紀商業(yè)評論;2015年07期
4 賈佳;王樹X ;劉媛;;“互聯(lián)網+醫(yī)藥企業(yè)”發(fā)展戰(zhàn)略[J];中外企業(yè)家;2015年18期
5 黃丹莉;;淺析供應鏈環(huán)境下醫(yī)藥商業(yè)企業(yè)的發(fā)展對策——以九州通醫(yī)藥集團為例[J];物流工程與管理;2015年05期
6 朱竟;景浩;;新醫(yī)改下民營醫(yī)藥商業(yè)企業(yè)的未來之路[J];遼寧中醫(yī)藥大學學報;2015年04期
7 劉南;段璐璐;干華棟;;基于行業(yè)價值鏈模型分析的我國醫(yī)藥流通行業(yè)發(fā)展對策研究[J];現(xiàn)代管理科學;2013年10期
8 張德書;戈文魯;;我國藥品生產流通市場現(xiàn)況分析[J];中國衛(wèi)生質量管理;2011年05期
9 連華慶;;淺析我國醫(yī)藥流通行業(yè)發(fā)展策略[J];商業(yè)經濟;2011年12期
10 趙可;;淺析我國藥品流通的現(xiàn)狀及發(fā)展[J];中國商貿;2011年06期
相關碩士學位論文 前4條
1 程萌;T醫(yī)藥公司發(fā)展戰(zhàn)略研究[D];北京交通大學;2011年
2 李克俊;湖南九芝堂醫(yī)藥有限公司競爭戰(zhàn)略研究[D];湖南大學;2009年
3 李江;M醫(yī)藥流通公司發(fā)展戰(zhàn)略研究[D];北京交通大學;2007年
4 石正軍;哈藥集團發(fā)展戰(zhàn)略研究[D];哈爾濱工程大學;2007年
,本文編號:2266695
本文鏈接:http://sikaile.net/jingjifazhanlunwen/2266695.html